Close Menu

NEW YORK – Bio-Techne on Tuesday announced that its fiscal 2021 second quarter revenues rose 21 percent year over year.

For the three months ended Dec. 31, 2020, the Minneapolis-based firm reported $224.3 million in revenues, up from $184.9 million a year ago and beating analysts' average estimate of $206.5 million.

In Q2, the firm reported Diagnostics and Genomics revenue of $52.5 million, up 20 percent year over year from $43.8 million, and Protein Sciences revenue of $172.2 million, up 22 percent from $141.5 million in the prior-year quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Sponsored by

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Sponsored by

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.